Acetylsalicylic Acid

High-dose aspirin with dichlorphenamide is contraindicated due to risk of anorexia, tachypnea, lethargy, and coma. Low-dose aspirin requires careful monitoring.

Cross reactivity between aspirin and NSAIDs including bronchospasm reported in aspirin-sensitive patients. Ibuprofen should not be administered to patients with aspirin sensitivity.

Aspirin and other salicylate drugs are additive to salsalate and may increase plasma concentrations of salicylic acid to toxic levels. Concomitant administration is not generally recommended.

Concomitant use of ibuprofen and aspirin increases risk of GI adverse reactions and bleeding; no greater therapeutic benefit than NSAID alone.

Concomitant use of NSAID and aspirin is associated with significantly increased incidence of GI adverse reactions and increased risk of bleeding.

See WARNINGS section for detailed interaction information.

Increased risk of major hemorrhagic events; monitor for bleeding and assess hemorrhage risk before initiation.

Increased risk of bleeding and major hemorrhagic events; greater anti-platelet aggregation when combined.

Antiplatelet agent that increases bleeding risk when coadministered with apixaban. Concomitant use increased major bleeding risk from 1.8% to 3.4% per year.

Concomitant use of celecoxib and aspirin is associated with significantly increased incidence of GI adverse reactions and increased risk of bleeding.

Concurrent use of aspirin with citalopram may potentiate the risk of upper gastrointestinal bleeding due to interference with serotonin reuptake and platelet hemostasis.

Concurrent use may potentiate risk of upper gastrointestinal bleeding due to interference with hemostasis and serotonin reuptake inhibition.

Concomitant use with corticosteroids increases risk of gastrointestinal side effects. Use cautiously in hypoprothrombinemia.

Concurrent use may potentiate risk of upper gastrointestinal bleeding when combined with desvenlafaxine.

Increased incidence of GI adverse reactions and increased risk of bleeding. Concomitant use not generally recommended at analgesic doses.

Concomitant use associated with significantly increased incidence of GI adverse reactions and increased risk of bleeding.

Concomitant use associated with significantly increased incidence of GI adverse reactions and increased risk of bleeding.

Concomitant use not generally recommended due to increased risk of bleeding and GI adverse reactions. No greater therapeutic benefit than NSAID alone.

Concomitant use associated with significantly increased incidence of GI adverse reactions and increased risk of bleeding.

Concomitant use associated with significantly increased incidence of GI adverse reactions and increased risk of bleeding.

Concomitant use significantly increases incidence of GI adverse reactions and bleeding risk compared to NSAID alone.

Concomitant use of analgesic doses is not generally recommended due to increased risk of bleeding.

Concomitant use with analgesic doses of aspirin significantly increases incidence of GI adverse reactions and bleeding risk.

Concomitant use increases risk of bleeding and GI adverse reactions compared to NSAID alone. No greater therapeutic benefit than NSAID monotherapy.

Concomitant use associated with significantly increased incidence of GI adverse reactions and increased risk of bleeding.

Concomitant use increases risk of bleeding and GI adverse reactions compared to NSAID alone. Not generally recommended at analgesic doses.

Concomitant use increases risk of bleeding. Clinical studies showed increased rates of clinically relevant bleeding with low-dose aspirin (≤100 mg/day).

May enhance risk of hemorrhage. Discontinue prior to Lovenox initiation if possible, or conduct close clinical and laboratory monitoring if coadministration is essential.

Coadministration increases the risk of bleeding.

Concurrent use may potentiate risk of upper gastrointestinal bleeding due to interference with hemostasis.

Concomitant use of fenoprofen and analgesic doses of aspirin is associated with significantly increased incidence of GI adverse reactions and increased risk of bleeding.

Pyridoxine interaction with Aspirin may increase bleeding risk.

Possibility of increased bleeding due to pyridoxine interaction with anticoagulants.

Concurrent use may potentiate risk of upper gastrointestinal bleeding due to interference with serotonin-mediated hemostasis.

Concurrent use may potentiate risk of upper gastrointestinal bleeding.

Increased incidence of GI adverse reactions and increased risk of bleeding. Aspirin lowers serum flurbiprofen concentrations.

Possibility of increased bleeding due to pyridoxine interaction with anticoagulants.

Possibility of increased bleeding due to folic acid interaction with anticoagulants.

Ibuprofen interferes with antiplatelet activity of aspirin and increases risk of GI adverse reactions and bleeding when used together.

Ibuprofen interferes with the antiplatelet activity of aspirin, increasing risk of cardiovascular events. Concomitant use is not generally recommended due to increased adverse effects.

Concomitant use associated with significantly increased incidence of GI adverse reactions and increased risk of bleeding.

Concomitant use increases risk of bleeding and GI adverse reactions. No additional therapeutic benefit compared to ketorolac alone.

Concomitant use associated with significantly increased incidence of GI adverse reactions and increased risk of bleeding.

Concomitant use associated with significantly increased incidence of GI adverse reactions and increased risk of bleeding.

Increased incidence of GI adverse reactions and increased risk of bleeding; no additional therapeutic benefit over NSAID alone.

Increased incidence of GI adverse reactions and increased risk of bleeding when combined with meloxicam.

Concomitant use of meloxicam and analgesic doses of aspirin is not generally recommended due to increased risk of bleeding and GI adverse reactions.

High-dose aspirin with methazolamide may cause anorexia, tachypnea, lethargy, coma, and death. Caution advised with concomitant high-dose use.

NSAID that may increase methotrexate plasma concentrations, increasing risk of severe adverse reactions and potentially reducing clinical effectiveness.

NSAID that may increase methotrexate plasma concentrations, increasing risk of severe adverse reactions and potentially reducing clinical effectiveness.

Concomitant use increases risk of gastrointestinal side effects. Aspirin should be used cautiously with corticosteroids in hypoprothrombinemia.

Pyridoxine in the multivitamin may increase bleeding risk when used with anticoagulants.

Naproxen interferes with antiplatelet effect of aspirin and increases risk of GI adverse reactions and bleeding when used together.

Naproxen interferes with antiplatelet effect of low-dose aspirin. Concomitant use with analgesic doses of aspirin increases GI adverse reactions and cardiovascular event risk.

Lower dose naproxen interferes with antiplatelet effect of low-dose aspirin; concomitant use increases GI adverse reactions and bleeding risk.

Lower dose naproxen interferes with antiplatelet effect of low-dose aspirin; concomitant use increases GI adverse reactions and bleeding risk.

Concomitant use associated with significantly increased incidence of GI adverse reactions and increased risk of bleeding.

Concurrent use of aspirin with paroxetine may potentiate the risk of bleeding.

Increased bleeding risk when combined with paroxetine due to platelet dysfunction. Inform patients of increased bleeding risk.

Increased risk of bleeding with concurrent use; inform patients of increased bleeding risk.

Concomitant use associated with significantly increased incidence of GI adverse reactions and increased risk of bleeding.

Concomitant use increases risk of gastrointestinal side effects; use cautiously in hypoprothrombinemia.

Platelet aggregation inhibitor coadministration may increase bleeding risk. Promptly evaluate signs/symptoms of blood loss.

Concurrent use may potentiate bleeding risk. Inform patients of increased bleeding risk.

Concurrent use may potentiate risk of bleeding.

Concomitant use of analgesic doses of aspirin with sumatriptan and naproxen sodium is not generally recommended. Aspirin interferes with hemostasis and increases bleeding risk.

Concomitant use increases risk of gastrointestinal side effects. Should be used cautiously with corticosteroids in hypoprothrombinemia.

Increased risk of upper gastrointestinal bleeding due to impaired serotonin reuptake affecting platelet hemostasis.

Bromelain may increase the risk of bleeding when combined with aspirin.

Concomitant therapy with daily doses of alendronate sodium greater than 10 mg and aspirin-containing products increases incidence of upper gastrointestinal adverse events.

Concomitant therapy with daily doses of alendronate greater than 10 mg and aspirin-containing products increased incidence of upper gastrointestinal adverse events.

Concomitant use of aspirin or other NSAIDs with corticosteroids requires monitoring.

Monitor patients for bleeding when taking ZYNRELEF concomitantly with aspirin, which interferes with hemostasis.

Low dose aspirin showed induction effect on CYP2C19, potentially decreasing carisoprodol exposure and increasing meprobamate exposure; full pharmacological impact unknown.

Acetylsalicylic acid may reduce efficacy of CAROSPIR. May require higher maintenance dose; monitor patient closely.

Concomitant use may potentiate risk of bleeding. Closely monitor for bleeding when desvenlafaxine is initiated or discontinued.

Concomitant use may potentiate bleeding risk. Closely monitor for bleeding when desvenlafaxine is initiated or discontinued.

Concomitant administration is not generally recommended due to potential for increased adverse effects. Aspirin reduces diflunisal protein binding and may decrease diflunisal levels.

Decreases protein binding and inhibits metabolism of valproate, increasing valproate free fraction 4-fold. Monitoring of valproate concentrations is recommended.

Decreases protein binding and inhibits metabolism of valproate, increasing free valproate fraction. Caution advised in co-administration.

Concurrent use may potentiate upper gastrointestinal bleeding risk due to serotonin reuptake inhibition effects on hemostasis.

May potentiate upper gastrointestinal bleeding risk when used with duloxetine.

Concurrent use may potentiate upper gastrointestinal bleeding risk due to duloxetine's effect on serotonin reuptake.

Concomitant use may potentiate risk of bleeding. Patients should be informed of increased bleeding risk.

Etodolac protein binding is reduced when co-administered with aspirin. Concomitant use is not generally recommended due to potential for increased adverse effects.

Increased ulcerogenic effect and decreased pharmacologic effect of aspirin. Risk of salicylate toxicity upon steroid discontinuation. Monitor salicylate levels and adjust dosage accordingly.

Concomitant use did not significantly affect pharmacokinetics/pharmacodynamics in clinical studies. Monitor patients closely for hemorrhage if co-administration is necessary.

Combination of furosemide and acetylsalicylic acid may temporarily reduce creatinine clearance.

May interfere with platelet aggregation and induce bleeding. Use with caution in heparinized patients; dose reduction of antiplatelet agent or heparin recommended.

Corticosteroids may increase aspirin clearance, leading to decreased salicylate levels or increased toxicity upon corticosteroid withdrawal. Use cautiously in hypoprothrombinemia patients.

Concomitant use increases risk of gastrointestinal side effects and requires caution in hypoprothrombinemia.

Concomitant use of aspirin and corticosteroids increases risk of gastrointestinal side effects. Aspirin should be used cautiously with corticosteroids in hypoprothrombinemia.

Caution should be exercised with concomitant use of aspirin and ibandronate as both are associated with gastrointestinal irritation.

Concurrent aspirin decreases ketoprofen protein binding and increases plasma clearance. Concomitant use is not generally recommended due to potential for increased adverse effects.

Antiplatelet drug that may potentiate bleeding risk when used with levomilnacipran. Closely monitor for bleeding.

Cyclooxygenase inhibitor may impact accuracy of MACRILEN diagnostic test by directly affecting pituitary growth hormone secretion. Avoid concomitant use.

Aspirin reduces meclofenamate sodium protein binding. Concomitant administration is not generally recommended due to potential for increased adverse effects.

Methylprednisolone may increase the clearance of chronic high dose aspirin, leading to decreased salicylate levels or increased toxicity upon withdrawal. Use cautiously in hypoprothrombinemia patients.

Concomitant use with corticosteroids increases risk of gastrointestinal side effects. Use cautiously in hypoprothrombinemia.

Concomitant use with corticosteroids increases risk of gastrointestinal side effects; use cautiously in hypoprothrombinemia.

Nabumetone's protein binding is reduced when administered with aspirin. Concomitant administration is not generally recommended due to potential increased adverse effects.

Concomitant aspirin may decrease the metabolic clearance of nicotinic acid, though clinical relevance is unclear.

Increases nitroglycerin maximum concentrations by up to 67% and AUC by 73%, potentially enhancing pharmacological effects. Monitor closely.

High-dose aspirin (3,900 mg daily) with nizatidine 150 mg twice daily resulted in increases in serum salicylate levels.

May potentiate the risk of bleeding when used with drugs that interfere with hemostasis.

Competes with penicillin G for renal tubular secretion, prolonging serum half-life.

Competes with penicillin G for renal tubular secretion, prolonging serum half-life of penicillin.

Competes with penicillin G for renal tubular secretion, prolonging serum half-life of penicillin.

Prednisone may increase clearance of high-dose chronic aspirin, leading to decreased salicylate levels or increased toxicity upon withdrawal. Use cautiously in hypoprothrombinemia.

Aspirin should be used cautiously in conjunction with corticotropin in patients with hypoprothrombinemia.

Regular aspirin use (≥3 days/week) was studied; upper gastrointestinal adverse experience incidence was similar between placebo and risedronate-treated patients. Monitor for GI effects.

ASA may reduce the efficacy of spironolactone. May require higher maintenance doses; monitor patient closely.

May reduce efficacy of spironolactone; higher maintenance doses may be needed.

Acetylsalicylic acid should be taken at least 1 hour before sucroferric oxyhydroxide to avoid reduced bioavailability.

Aspirin significantly depressed plasma levels of active sulfide metabolite and increased incidence of gastrointestinal adverse experiences; combination not recommended.

Concomitant administration of tolmetin sodium and aspirin is not generally recommended because of the potential for increased adverse effects.

Concomitant use with trazodone may increase risk of gastrointestinal bleeding. Monitor patients for bleeding risk.

Concomitant use increases risk of gastrointestinal side effects; use cautiously in hypoprothrombinemia.

Aspirin decreases protein binding of valproate and inhibits its metabolism, increasing valproate free fraction 4-fold and decreasing β-oxidation pathway. Monitoring of valproate concentrations is recommended.

Decreases protein binding and inhibits metabolism of valproate, increasing valproate free fraction 4-fold. Monitoring of valproate concentrations recommended.

May potentiate risk of upper gastrointestinal bleeding when used with venlafaxine due to serotonin reuptake inhibition affecting platelet hemostasis.

Coadministration has led to increased bleeding times greater than observed with aspirin alone in few reported cases.

Antiplatelet agent may potentiate risk of bleeding when used with vortioxetine. Monitor patients for increased bleeding risk.

Aspirin increases zafirlukast mean plasma levels by approximately 45%.

Caffeine may increase the metabolism of aspirin.

No drug-drug interactions have been demonstrated between argatroban and aspirin.

Limited data suggest no clinical interaction between aspirin and beta-blockers in acute myocardial infarction setting.

Used concomitantly in clinical studies without evidence of clinically significant adverse interactions.

Misoprostol does not interfere with beneficial effects of aspirin or exert clinically significant effects on absorption, blood levels, and antiplatelet effects of therapeutic doses.

Prazosin has been administered without adverse drug interaction with aspirin in limited clinical experience.

Administered without adverse drug interaction in limited clinical experience.

Peak plasma concentrations and AUC of rimantadine were reduced approximately 10% in the presence of aspirin.

Terazosin has been used concomitantly with aspirin in at least 50 patients with no interactions observed.

Used concomitantly with terazosin in at least 50 patients with no interactions observed.

Interaction noted in WARNINGS section; specific details refer to warnings for severity information.

Interaction noted in WARNINGS section; specific details not provided in this excerpt.